Loading patent…
AssigneesTechnophage, InvestigaçãO E Desenvolvimento Em Biotecnologia, SA, Tecnifar—Industria Tecnica Farmaceutica, S.A.
InventorsMiguel Angelo Da Costa Garcia, Carlos Jorge Sousa De Sao Jose, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marcal Da Silva, Sara Ferreira Llorente Grancho Lourenco
Estimating the term…
The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
A method of treating or reducing the incidence of an Acinetobacter baumanni bacterial infection in a subject in need thereof, said method comprising administering to said subject an effective amount of a pharmaceutical composition comprising a purified bacteriophage having a nucleic acid sequence of SEQ ID NO:760 and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.